Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LIMN

Liminatus Pharma Inc

Feb 13 • 04:00PM ET

0.3760

-0.1091 -22.49 %

Healthcare • Biotechnology • USA • NASD

Feb 13, 2:01 PMRecent S-1 filing for $9M dilutive share and warrant offering triggered sustained selling pressure into today's sharp decline.

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	79.47%	Shs Outstand	27.06M	Perf Week	-79.57%
Market Cap	11.68M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.56M	Perf Month	-49.87%
Enterprise Value	12.40M	PEG	-	EPS next Q	-	Inst Own	0.75%	Short Float	1.08%	Perf Quarter	-67.86%
Income	-2.58M	P/S	-	EPS this Y	-	Inst Trans	3.84%	Short Ratio	0.01	Perf Half Y	-90.87%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-116.93%	Short Interest	0.06M	Perf YTD	-38.36%
Book/sh	-0.06	P/C	16.22	EPS next 5Y	-	ROE	-	52W High	33.66 -98.88%	Perf Year	-96.76%
Cash/sh	0.02	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	0.47 -20.84%	Perf 3Y	-96.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	65.09% 35.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.82%	Oper. Margin	-	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.94	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.42	EPS Q/Q	24.67%	SMA20	-58.21%	Beta	0.43	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-54.53%	Rel Volume	0.91	Prev Close	0.49
Employees	3	LT Debt/Eq	-	Earnings	-	SMA200	-91.04%	Avg Volume	7.09M	Price	0.38
IPO	May 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	6,472,808	Change	-22.49%

Oct-30-25 10:04AM	Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +22.66%
Aug-05-25 12:11PM	BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Jul-28-25 07:30AM	Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative (GlobeNewswire) -7.23%
Jul-25-25 08:31AM	Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies (GlobeNewswire)
08:31AM	Loading…
Jul-24-25 08:31AM	Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy (GlobeNewswire) +30.91%
Jul-22-25 01:30PM	Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy (GlobeNewswire)

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIMN

Liminatus Pharma Inc

Upgrade your FINVIZ experience